David Hoang
Stock Analyst at Deutsche Bank
(3.12)
# 1,082
Out of 5,090 analysts
47
Total ratings
48.65%
Success rate
2.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $29.52 | +52.44% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $247.99 | +12.91% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $33.45 | +28.55% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $39.83 | -9.62% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $22.26 | -46.09% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $27.44 | +27.55% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $45.01 | +48.86% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $19.96 | +55.31% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $9.55 | +580.63% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $149.22 | +17.95% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $21.34 | -43.77% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $155.51 | +1.60% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.86 | +276.34% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.77 | +177.30% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.28 | +273.83% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $458.12 | -51.98% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $61.44 | +30.21% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $3.33 | -9.91% | 1 | Dec 7, 2022 |
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $29.52
Upside: +52.44%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $247.99
Upside: +12.91%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $33.45
Upside: +28.55%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $39.83
Upside: -9.62%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $22.26
Upside: -46.09%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $27.44
Upside: +27.55%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $45.01
Upside: +48.86%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $19.96
Upside: +55.31%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $9.55
Upside: +580.63%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $149.22
Upside: +17.95%
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $21.34
Upside: -43.77%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $155.51
Upside: +1.60%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.86
Upside: +276.34%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.77
Upside: +177.30%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.28
Upside: +273.83%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $458.12
Upside: -51.98%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $61.44
Upside: +30.21%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $3.33
Upside: -9.91%